|  | Alternative Medicine | Osteopathy

Chondroblastic Osteosarcoma: Aggressive Bone Cancer in Youth

Chondroblastic osteosarcoma (COS) is a high-grade malignant bone tumor producing cartilage matrix. It comprises ~10–25% of osteosarcomas.

Epidemiology

  • Peak incidence: 10–25 years (adolescents/young adults).
  • Slight male predominance.
  • Common sites: Distal femur, proximal tibia, proximal humerus.

Presentation

  • Pain (night, activity-related), swelling, palpable mass.
  • Pathologic fracture (10–15%).
  • Systemic: Fever, weight loss, fatigue (advanced).

Diagnosis

  • X-ray: Mixed lytic/sclerotic lesion, "sunburst" periosteal reaction, Codman's triangle.
  • MRI: Marrow/soft tissue extent; skip metastases.
  • Chest CT: Pulmonary metastases (most common site).
  • Biopsy: Core needle; confirms cartilage-producing malignant cells.

Treatment

  1. Neoadjuvant chemotherapy: MAP regimen (methotrexate, doxorubicin, cisplatin) ± ifosfamide.
  2. Wide surgical resection: Limb-salvage (endoprosthesis, allograft) or amputation.
  3. Adjuvant chemotherapy: Tailored to histologic response (necrosis %).

Prognosis

5-year survival: ~60–70% localized; <30% metastatic. Poor histologic response (<90% necrosis) worsens outlook.

Multidisciplinary sarcoma center care is essential.

Osteopathy - Related Articles